Conditions: Pulmonary Hypertension
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 2
Healthy volunteers: no

Brief summary:
This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with pulmonary hypertension. Subjects will undergo cardiopulmonary exercise testing at baseline, and after 4 weeks treatment with Anakinra (recombinant human Interleukin-1 receptor antagonist.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Anakinra 100 mg subcutaneously daily
Intervention descriptions: intervention 1: Anakinra 100 mg subcutaneously daily

Protocol document: